|
US5703055A
(en)
*
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
WO1991007425A1
(en)
|
1989-11-20 |
1991-05-30 |
Oncogen Limited Partnership |
Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
|
|
FR2676072B1
(fr)
|
1991-05-03 |
1994-11-18 |
Transgene Sa |
Vecteur de delivrance d'arn.
|
|
GB9406498D0
(en)
|
1994-03-31 |
1994-05-25 |
Smithkline Beecham Biolog |
Novel compounds
|
|
JP4111403B2
(ja)
|
1996-10-11 |
2008-07-02 |
ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア |
免疫刺激ポリヌクレオチド／免疫調節分子複合体
|
|
US6589940B1
(en)
|
1997-06-06 |
2003-07-08 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
|
WO1999014346A2
(en)
|
1997-09-19 |
1999-03-25 |
Sequitur, Inc. |
SENSE mRNA THERAPY
|
|
AU1774299A
(en)
|
1997-12-24 |
1999-07-19 |
Imperial Cancer Research Technology Limited |
Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
|
|
US6432925B1
(en)
|
1998-04-16 |
2002-08-13 |
John Wayne Cancer Institute |
RNA cancer vaccine and methods for its use
|
|
US20050112141A1
(en)
|
2000-08-30 |
2005-05-26 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
|
WO2002061113A2
(en)
|
2001-02-01 |
2002-08-08 |
The Johns Hopkins University |
Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
|
|
EP1903054A3
(de)
|
2001-06-05 |
2008-07-23 |
CureVac GmbH |
Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie
|
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
|
CN1129667C
(zh)
*
|
2001-12-26 |
2003-12-03 |
中国人民解放军第二军医大学 |
治疗肿瘤的自体免疫细胞及其制备方法
|
|
US20040175813A1
(en)
*
|
2002-05-24 |
2004-09-09 |
Kimberly Kline |
Mutant P53 proteins and uses thereof
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
ATE527281T1
(de)
|
2004-07-16 |
2011-10-15 |
Us Gov Health & Human Serv |
Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
|
|
DE102004035227A1
(de)
|
2004-07-21 |
2006-02-16 |
Curevac Gmbh |
mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
|
|
SE0402025D0
(sv)
|
2004-08-13 |
2004-08-13 |
Active Biotech Ab |
Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
|
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
|
EP2083088A3
(en)
|
2005-04-07 |
2009-10-14 |
Novartis Vaccines and Diagnostics, Inc. |
Cancer-related genes
|
|
ES2564823T3
(es)
|
2005-05-27 |
2016-03-29 |
Ospedale San Raffaele S.R.L. |
Vector génico que comprende miARN
|
|
HUE043492T2
(hu)
|
2005-08-23 |
2019-08-28 |
Univ Pennsylvania |
Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
JP4860702B2
(ja)
|
2005-10-21 |
2012-01-25 |
エフ．ホフマン−ラ ロシュ アーゲー |
ポリペプチドのリコンビナント発現のための方法
|
|
US7767210B2
(en)
|
2005-12-14 |
2010-08-03 |
The Board Of Regents Of The University Of Oklahoma |
RNA virus vaccines and methods
|
|
US20090186042A1
(en)
|
2006-02-27 |
2009-07-23 |
Arizona Board Of Regents For And On Behalf Of Arizona State University |
Identification and use of novopeptides for the treatment of cancer
|
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
JP2010519203A
(ja)
|
2007-02-16 |
2010-06-03 |
メルク・シャープ・エンド・ドーム・コーポレイション |
生物活性分子の活性を強化するための組成物及び方法
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
SI2644192T1
(sl)
|
2007-09-28 |
2017-08-31 |
Pfizer Inc. |
Ciljanje rakavih celic z uporabo nanodelcev
|
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
NZ588583A
(en)
|
2008-04-15 |
2012-08-31 |
Protiva Biotherapeutics Inc |
Novel lipid formulations for nucleic acid delivery
|
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
|
US9394538B2
(en)
|
2008-05-07 |
2016-07-19 |
Shi-Lung Lin |
Development of universal cancer drugs and vaccines
|
|
DK3156069T3
(da)
|
2008-06-20 |
2020-09-21 |
Univ Duke |
Sammensætninger, fremgangsmåder, og kits til fremkaldelse af et immunrespons
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
AU2015210364B2
(en)
|
2008-10-09 |
2017-03-09 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
US8343498B2
(en)
|
2008-10-12 |
2013-01-01 |
Massachusetts Institute Of Technology |
Adjuvant incorporation in immunonanotherapeutics
|
|
EP4241767B1
(en)
|
2008-11-10 |
2024-10-23 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
|
WO2010057203A2
(en)
|
2008-11-17 |
2010-05-20 |
The Board Of Regents Of The University Of Texas System |
Hdl particles for delivery of nucleic acids
|
|
US20120101148A1
(en)
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
|
CA2753362C
(en)
|
2009-02-24 |
2018-06-19 |
The Scripps Research Institute |
Reengineering mrna primary structure for enhanced protein production
|
|
TR201811076T4
(tr)
|
2009-06-10 |
2018-08-27 |
Arbutus Biopharma Corp |
Geliştirilmiş lipit formulasyonu.
|
|
US8283333B2
(en)
|
2009-07-01 |
2012-10-09 |
Protiva Biotherapeutics, Inc. |
Lipid formulations for nucleic acid delivery
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
CN107028886A
(zh)
|
2009-11-04 |
2017-08-11 |
不列颠哥伦比亚大学 |
含有核酸的脂质粒子及相关的方法
|
|
PL3338765T3
(pl)
|
2009-12-01 |
2019-06-28 |
Translate Bio, Inc. |
Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
|
|
AU2010334911A1
(en)
|
2009-12-23 |
2012-07-12 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
|
KR102095670B1
(ko)
|
2010-05-14 |
2020-03-31 |
더 제너럴 하스피톨 코포레이션 |
종양 특이적 신생항원을 확인하는 조성물 및 방법
|
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
AU2011276234B2
(en)
|
2010-07-06 |
2016-02-25 |
Glaxosmithkline Biologicals S.A. |
Liposomes with lipids having an advantageous pKa- value for RNA delivery
|
|
ES2646669T3
(es)
|
2010-07-06 |
2017-12-14 |
Glaxosmithkline Biologicals Sa |
Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
MX346784B
(es)
|
2010-11-12 |
2017-03-31 |
Inovio Pharmaceuticals Inc |
Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
EP2697367B1
(en)
|
2011-04-13 |
2018-12-19 |
Immunicum AB |
Method for proliferation of antigen-specific t cells
|
|
EP2701686A4
(en)
|
2011-04-28 |
2014-11-05 |
Stc Unm |
LIPID BINCHES SUPPORTED ON POROUS NANOPARTICLES (PROTOCELLS) FOR TARGETED ADMINISTRATION, AND METHODS OF USE THEREOF
|
|
ES2639122T3
(es)
|
2011-05-13 |
2017-10-25 |
Zoetis Services Llc |
Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah
|
|
CN103687957A
(zh)
|
2011-05-17 |
2014-03-26 |
现代治疗公司 |
工程化核酸及其用于非人类脊椎动物的方法
|
|
PL3892295T3
(pl)
*
|
2011-05-24 |
2023-07-24 |
BioNTech SE |
Zindywidualizowane szczepionki przeciwnowotworowe
|
|
WO2012159643A1
(en)
|
2011-05-24 |
2012-11-29 |
Biontech Ag |
Individualized vaccines for cancer
|
|
RU2649133C2
(ru)
*
|
2011-07-06 |
2018-03-29 |
Новартис Аг |
Катионные эмульсии масло-в-воде
|
|
EP2746404B1
(en)
|
2011-08-16 |
2017-12-06 |
Taiho Pharmaceutical Co., Ltd. |
Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
|
|
SG11201400250UA
(en)
|
2011-08-31 |
2014-03-28 |
Novartis Ag |
Pegylated liposomes for delivery of immunogen-encoding rna
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2013039861A2
(en)
|
2011-09-12 |
2013-03-21 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof
|
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
WO2013130161A1
(en)
|
2011-12-14 |
2013-09-06 |
modeRNA Therapeutics |
Methods of responding to a biothreat
|
|
JP2015501844A
(ja)
|
2011-12-16 |
2015-01-19 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
|
|
CN104968354A
(zh)
|
2011-12-21 |
2015-10-07 |
现代治疗公司 |
增加器官或器官外植体的活力或寿命的方法
|
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US20140275229A1
(en)
|
2012-04-02 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
WO2013151771A1
(en)
|
2012-04-05 |
2013-10-10 |
Massachusetts Institute Of Technology |
Immunostimulatory compositions and methods of use thereof
|
|
ES2719598T3
(es)
|
2012-05-25 |
2019-07-11 |
Curevac Ag |
Inmovilización reversible y/o liberación controlada de ácidos nucleicos contenidos en nanopartículas mediante revestimientos poliméricos (biodegradables)
|
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
|
EP2914728B1
(en)
|
2012-11-01 |
2020-07-08 |
Factor Bioscience Inc. |
Methods and products for expressing proteins in cells
|
|
ES2921623T3
(es)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
ARN modificado terminalmente
|
|
EP2925348B1
(en)
*
|
2012-11-28 |
2019-03-06 |
BioNTech RNA Pharmaceuticals GmbH |
Individualized vaccines for cancer
|
|
US9687448B2
(en)
|
2012-12-07 |
2017-06-27 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid lipid particle formulations
|
|
US20150315541A1
(en)
|
2012-12-13 |
2015-11-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
|
EP2931319B1
(en)
|
2012-12-13 |
2019-08-21 |
ModernaTX, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
WO2014127917A1
(en)
|
2013-02-22 |
2014-08-28 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
BR122021025267B1
(pt)
|
2013-02-22 |
2023-12-05 |
Curevac Ag |
Partes de kit e composição farmacêutica compreendendo um inibidor da via de pd-1
|
|
EP3608308B1
(en)
|
2013-03-08 |
2021-07-21 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
|
US20160024181A1
(en)
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
JP6445523B2
(ja)
|
2013-03-15 |
2018-12-26 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
生体分子アジュバントを含むワクチン
|
|
EP2983804A4
(en)
|
2013-03-15 |
2017-03-01 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
EP2971033B8
(en)
|
2013-03-15 |
2019-07-10 |
ModernaTX, Inc. |
Manufacturing methods for production of rna transcripts
|
|
WO2014172045A1
(en)
|
2013-03-15 |
2014-10-23 |
The University Of British Columbia |
Lipid nanoparticles for transfection and related methods
|
|
WO2014144039A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
EP2971161B1
(en)
|
2013-03-15 |
2018-12-26 |
ModernaTX, Inc. |
Ribonucleic acid purification
|
|
BR112015025460B1
(pt)
|
2013-04-07 |
2024-01-02 |
The Broad Institute, Inc. |
Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
WO2015050158A1
(ja)
|
2013-10-01 |
2015-04-09 |
国立大学法人三重大学 |
抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン
|
|
WO2015051169A2
(en)
|
2013-10-02 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
US20160243221A1
(en)
|
2013-10-18 |
2016-08-25 |
Moderna Therapeutics, Inc. |
Compositions and methods for tolerizing cellular systems
|
|
WO2015061467A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Lipid formulations for delivery of messenger rna
|
|
WO2015085318A2
(en)
|
2013-12-06 |
2015-06-11 |
Moderna Therapeutics, Inc. |
Targeted adaptive vaccines
|
|
EP3082760A1
(en)
|
2013-12-19 |
2016-10-26 |
Novartis AG |
LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
|
|
WO2015095346A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
NZ721908A
(en)
|
2013-12-20 |
2022-12-23 |
Massachusetts Gen Hospital |
Combination therapy with neoantigen vaccine
|
|
DK3134131T3
(en)
|
2014-04-23 |
2022-02-07 |
Modernatx Inc |
Nucleic acid vaccines
|
|
WO2015196128A2
(en)
|
2014-06-19 |
2015-12-23 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
IL316479A
(en)
*
|
2014-06-25 |
2024-12-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
EP3169783A4
(en)
|
2014-07-17 |
2018-10-03 |
Modernatx, Inc. |
Terminal modifications of polynucleotides
|
|
ES2946969T3
(es)
|
2014-12-12 |
2023-07-28 |
CureVac SE |
Moléculas de ácido nucleico artificiales para una expresión proteica mejorada
|
|
WO2016118724A1
(en)
|
2015-01-21 |
2016-07-28 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
WO2016149384A1
(en)
|
2015-03-18 |
2016-09-22 |
University Of Massachusetts |
Virus-like particle compositions and vaccines against epstein-barr virus infection and disease
|
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
EP3173092B1
(en)
|
2015-04-22 |
2019-06-26 |
CureVac AG |
Rna containing composition for treatment of tumor diseases
|
|
CN113564168B
(zh)
|
2015-04-23 |
2024-10-25 |
美国杰龙生物医药公司 |
使用多价阳离子盐组合物制备多核苷酸的方法
|
|
JP6851983B2
(ja)
|
2015-05-01 |
2021-03-31 |
イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． |
デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法
|
|
EP3294324A1
(en)
|
2015-05-13 |
2018-03-21 |
Agenus Inc. |
Vaccines for treatment and prevention of cancer
|
|
JP6893177B2
(ja)
|
2015-05-15 |
2021-06-23 |
キュアバック アーゲー |
少なくとも１つのｍＲＮＡコンストラクトの投与を含むプライムブーストレジメン（ＰＲＩＭＥ−ＢＯＯＳＴ ＲＥＧＩＭＥＮＳ）
|
|
PL4108769T3
(pl)
|
2015-05-29 |
2024-02-05 |
CureVac Manufacturing GmbH |
Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym
|
|
EP3307305A4
(en)
|
2015-06-10 |
2019-05-22 |
Modernatx, Inc. |
TARGETED ADAPTIVE VACCINES
|
|
WO2016203025A1
(en)
|
2015-06-17 |
2016-12-22 |
Curevac Ag |
Vaccine composition
|
|
WO2017011773A2
(en)
|
2015-07-15 |
2017-01-19 |
Modernatx, Inc. |
Codon-optimized nucleic acids encoding antibodies
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
WO2017020026A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
WO2017019935A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Multimeric mrna
|
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
WO2017031241A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
|
RS63030B1
(sr)
|
2015-09-17 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
|
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
AU2016342048B2
(en)
|
2015-10-22 |
2022-09-08 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
|
AU2016342376A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
EP3365009A4
(en)
|
2015-10-22 |
2019-07-03 |
ModernaTX, Inc. |
VACCINES AGAINST HERPES SIMPLEX VIRUS
|
|
WO2017070601A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
CN108430456B
(zh)
|
2015-10-22 |
2022-01-18 |
摩登纳特斯有限公司 |
癌症疫苗
|
|
TN2018000154A1
(en)
|
2015-10-22 |
2019-10-04 |
Modernatx Inc |
Respiratory syncytial virus vaccine
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
RS63986B1
(sr)
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
WO2017081082A2
(en)
|
2015-11-09 |
2017-05-18 |
Curevac Ag |
Optimized nucleic acid molecules
|
|
CA3007955A1
(en)
|
2015-12-10 |
2017-06-15 |
Modernatx, Inc. |
Lipid nanoparticles for delivery of therapeutic agents
|
|
KR102883915B1
(ko)
|
2015-12-16 |
2025-11-18 |
시애틀 프로젝트 코포레이션 |
신생항원 동정, 제조, 및 용도
|
|
EP3390630B1
(en)
|
2015-12-17 |
2025-01-22 |
ModernaTX, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
JP7114465B2
(ja)
|
2015-12-22 |
2022-08-08 |
モデルナティエックス インコーポレイテッド |
薬剤の細胞内送達のための化合物および組成物
|
|
US10465190B1
(en)
|
2015-12-23 |
2019-11-05 |
Modernatx, Inc. |
In vitro transcription methods and constructs
|
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
|
MA45032A
(fr)
|
2016-05-18 |
2019-03-27 |
Fundacion Para La Investig Medica Aplicada |
Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë
|
|
US12123030B2
(en)
|
2016-05-18 |
2024-10-22 |
Modernatx, Inc. |
Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
|
|
WO2017201349A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
|
US11001861B2
(en)
|
2016-05-18 |
2021-05-11 |
Modernatx, Inc. |
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
|
|
EP3458092A1
(en)
|
2016-05-18 |
2019-03-27 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
EP3896164A1
(en)
|
2016-05-18 |
2021-10-20 |
ModernaTX, Inc. |
Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease
|
|
MA45053A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique
|
|
US20190382774A1
(en)
|
2016-05-18 |
2019-12-19 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
JP7088911B2
(ja)
|
2016-05-18 |
2022-06-21 |
モデルナティエックス インコーポレイテッド |
リラキシンをコードするポリヌクレオチド
|
|
WO2017218704A1
(en)
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
JP6987338B2
(ja)
|
2016-08-05 |
2021-12-22 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ＭＨＣＩＩ拘束性ＣＤ４＋ＦＯＸＰ３＋制御性Ｔ細胞のｅｘ ｖｉｖｏ生成及びその治療的使用
|
|
CA3025812A1
(en)
|
2016-08-19 |
2018-02-22 |
Curevac Ag |
Rna for cancer therapy
|
|
JP6983455B2
(ja)
|
2016-09-14 |
2021-12-17 |
モデルナティーエックス， インコーポレイテッド |
高純度ｒｎａ組成物及びその調製のための方法
|
|
AU2017345766A1
(en)
|
2016-10-21 |
2019-05-16 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
MX2019004913A
(es)
|
2016-10-26 |
2019-09-16 |
Curevac Ag |
Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
|
|
WO2018081462A1
(en)
|
2016-10-26 |
2018-05-03 |
Modernatx, Inc. |
Methods and compositions for rna mapping
|
|
EP3532070A1
(en)
|
2016-10-26 |
2019-09-04 |
Modernatx, Inc. |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
|
EP3532097A1
(en)
|
2016-10-27 |
2019-09-04 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN110167587A
(zh)
|
2016-11-11 |
2019-08-23 |
摩登纳特斯有限公司 |
流感疫苗
|
|
EP3551193A4
(en)
|
2016-12-08 |
2020-08-19 |
Modernatx, Inc. |
NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
|
|
EP3555289A1
(en)
|
2016-12-13 |
2019-10-23 |
ModernaTX, Inc. |
Rna affinity purification
|
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
|
WO2018140826A1
(en)
|
2017-01-27 |
2018-08-02 |
The Methodist Hospital |
Core/shell structure platform for immunotherapy
|
|
RU2768829C2
(ru)
|
2017-02-01 |
2022-03-24 |
МОДЕРНАТиЭкс, ИНК. |
Противораковые рнк-вакцины
|
|
EP3576780A1
(en)
|
2017-02-01 |
2019-12-11 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
|
US20200032274A1
(en)
|
2017-02-01 |
2020-01-30 |
Moderna TX, Inc. |
Polynucleotide secondary structure
|
|
WO2018151816A1
(en)
|
2017-02-16 |
2018-08-23 |
Modernatx, Inc. |
High potency immunogenic compositions
|
|
US20200368162A1
(en)
|
2017-02-24 |
2020-11-26 |
Modernatx, Inc. |
Nucleic Acid-Based Therapy of Muscular Dystrophies
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
MA47787A
(fr)
|
2017-03-15 |
2020-01-22 |
Modernatx Inc |
Vaccin contre le virus respiratoire syncytial
|
|
ES3020935T3
(en)
|
2017-03-15 |
2025-05-23 |
Modernatx Inc |
Lipid nanoparticle formulation
|
|
KR20190132405A
(ko)
|
2017-03-15 |
2019-11-27 |
모더나티엑스, 인크. |
치료제의 세포내 전달을 위한 화합물 및 조성물
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
WO2018170347A1
(en)
|
2017-03-17 |
2018-09-20 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
WO2018175783A1
(en)
|
2017-03-22 |
2018-09-27 |
Modernatx, Inc. |
Rna bacterial vaccines
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
EP3612965A4
(en)
|
2017-04-19 |
2021-01-13 |
Gritstone Oncology, Inc. |
NEOANTIGEN IDENTIFICATION, MANUFACTURING AND USE
|
|
WO2018200737A1
(en)
|
2017-04-26 |
2018-11-01 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018220553A1
(en)
|
2017-05-30 |
2018-12-06 |
Glaxosmithkline Biologicals Sa |
Methods for manufacturing a liposome encapsulated rna
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
|
US20200165593A1
(en)
|
2017-07-21 |
2020-05-28 |
Modernatx, Inc. |
Modified mRNA Encoding a Propionyl-CoA Carboxylase and Uses Thereof
|
|
WO2019036670A2
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
EFFECTIVE MRNA VACCINES
|
|
WO2019036683A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
ANALYTICAL METHODS BY HPLC
|
|
WO2019036685A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR HPLC ANALYSIS
|
|
CN111212905A
(zh)
|
2017-08-18 |
2020-05-29 |
摩登纳特斯有限公司 |
Rna聚合酶变体
|
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
|
US20190192646A1
(en)
|
2017-11-03 |
2019-06-27 |
Modernatx, Inc. |
Salmonella vaccines
|
|
CA3083102A1
(en)
|
2017-11-21 |
2019-05-31 |
Modernatx, Inc. |
Epstein-barr virus vaccines
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
CA3095216A1
(en)
|
2018-02-28 |
2019-09-06 |
University Of Washington |
Self-asssembling nanostructure vaccines
|
|
CA3093509A1
(en)
|
2018-03-15 |
2019-09-19 |
Biontech Rna Pharmaceuticals Gmbh |
5'-cap-tri nucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy
|
|
MX2020012649A
(es)
|
2018-05-25 |
2021-07-02 |
The Wistar Inst |
Neoantígenos especificos de tumor y métodos de uso de estos.
|
|
SG11202012770RA
(en)
|
2018-06-27 |
2021-01-28 |
Modernatx Inc |
Personalized cancer vaccine epitope selection
|
|
WO2020020444A1
(en)
|
2018-07-24 |
2020-01-30 |
Biontech Rna Pharmaceuticals Gmbh |
Individualized vaccines for cancer
|
|
US20220349010A1
(en)
|
2018-07-26 |
2022-11-03 |
Frame Pharmaceuticals B.V. |
Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
|
|
WO2020037102A1
(en)
|
2018-08-15 |
2020-02-20 |
University Of Florida Research Foundation, Inc. |
Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
|
|
AU2019338557A1
(en)
|
2018-09-13 |
2021-03-25 |
Modernatx, Inc. |
Modified mRNA for the treatment of progressive familial intrahepatic cholestasis disorders
|
|
US12151029B2
(en)
|
2018-09-19 |
2024-11-26 |
Modernatx, Inc. |
PEG lipids and uses thereof
|
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
CA3118947A1
(en)
|
2018-11-07 |
2020-05-14 |
Modernatx, Inc. |
Rna cancer vaccines
|
|
AU2019404547B2
(en)
|
2018-12-21 |
2025-01-30 |
Biontech Us Inc. |
Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
|
|
WO2020146814A1
(en)
|
2019-01-11 |
2020-07-16 |
Northwestern University |
Bioconjugate vaccines' synthesis in prokaryotic cell lysates
|
|
EP3911678A1
(en)
|
2019-01-14 |
2021-11-24 |
Genentech, Inc. |
Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
US11851694B1
(en)
|
2019-02-20 |
2023-12-26 |
Modernatx, Inc. |
High fidelity in vitro transcription
|
|
JP2022521094A
(ja)
|
2019-02-20 |
2022-04-05 |
モデルナティエックス インコーポレイテッド |
共転写キャッピング用ｒｎａポリメラーゼバリアント
|
|
CN113874502A
(zh)
|
2019-03-11 |
2021-12-31 |
摩登纳特斯有限公司 |
补料分批体外转录方法
|
|
WO2020190750A1
(en)
|
2019-03-15 |
2020-09-24 |
Modernatx, Inc. |
Hiv rna vaccines
|
|
JP2022535006A
(ja)
|
2019-05-31 |
2022-08-04 |
モデルナティエックス インコーポレイテッド |
増殖ｔ細胞アッセイ
|
|
WO2021016430A1
(en)
|
2019-07-23 |
2021-01-28 |
Translate Bio, Inc. |
Stable compositions of mrna-loaded lipid nanoparticles and processes of making
|
|
CN114269918A
(zh)
|
2019-08-14 |
2022-04-01 |
摩登纳特斯有限公司 |
用于纯化体外转录的下游产物的方法
|
|
JP2022547313A
(ja)
|
2019-09-11 |
2022-11-11 |
モデルナティエックス インコーポレイテッド |
ヒトサイトメガロウイルスワクチン
|
|
MX2022003269A
(es)
|
2019-09-19 |
2022-07-04 |
Modernatx Inc |
Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos.
|
|
CA3155014A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Cap guides and methods of use thereof for rna mapping
|
|
CN110974954B
(zh)
|
2019-12-24 |
2021-03-16 |
珠海丽凡达生物技术有限公司 |
一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
|
|
MX2022007905A
(es)
|
2019-12-31 |
2022-08-25 |
Elixirgen Therapeutics Inc |
Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos.
|
|
EP4088281A4
(en)
|
2020-01-10 |
2024-02-21 |
ModernaTX, Inc. |
VARIOUS AUTOCECODER FOR GENERATING BIOLOGICAL SEQUENCE
|
|
US20210228707A1
(en)
|
2020-01-28 |
2021-07-29 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
|
JP2023513073A
(ja)
|
2020-01-30 |
2023-03-30 |
モデルナティエックス インコーポレイテッド |
呼吸器系ウイルス免疫化組成物
|
|
CN116133652A
(zh)
|
2020-01-31 |
2023-05-16 |
摩登纳特斯有限公司 |
制备脂质纳米粒子的方法
|
|
KR20220136378A
(ko)
|
2020-01-31 |
2022-10-07 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 rna 백신을 이용하여 네오에피토프-특이적 t 세포를 유도하는 방법
|
|
AU2021215938A1
(en)
|
2020-02-07 |
2022-09-01 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines
|
|
EP4103172A4
(en)
*
|
2020-02-11 |
2024-05-01 |
Genevant Sciences Gmbh |
CATIONIC LIPIDS FOR THE DELIVERY OF LIPID NANOPARTICLES OF THERAPEUTIC AGENTS TO HEPATIC STELLAR CELLS
|
|
WO2021211343A1
(en)
|
2020-04-13 |
2021-10-21 |
Modernatx, Inc. |
Zika virus mrna vaccines
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
US20230181481A1
(en)
|
2020-05-15 |
2023-06-15 |
Modernatx, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating covid-19
|
|
US20230190761A1
(en)
|
2020-05-21 |
2023-06-22 |
Modernatx, Inc. |
Methylene blue stabilized mrna compositions
|
|
AU2021283934A1
(en)
|
2020-06-05 |
2023-01-19 |
Modernatx, Inc. |
Bacterial strains for DNA production
|
|
JP2023538260A
(ja)
|
2020-08-06 |
2023-09-07 |
モダーナティエックス・インコーポレイテッド |
ペイロード分子を気道上皮に送達するための組成物
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
WO2022067010A1
(en)
|
2020-09-25 |
2022-03-31 |
Modernatx, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|
|
WO2022150717A1
(en)
|
2021-01-11 |
2022-07-14 |
Modernatx, Inc. |
Seasonal rna influenza virus vaccines
|
|
JP2024503698A
(ja)
|
2021-01-15 |
2024-01-26 |
モデルナティエックス インコーポレイテッド |
変異型株ベースのコロナウイルスワクチン
|
|
US20240139309A1
(en)
|
2021-01-15 |
2024-05-02 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
|
IL305644A
(en)
|
2021-03-05 |
2023-11-01 |
Modernatx Inc |
Vlp enteroviral vaccines
|
|
US20240299531A1
(en)
|
2021-03-15 |
2024-09-12 |
Moderna TX, Inc |
Therapeutic use of sars-cov-2 mrna domain vaccines
|
|
JP2024511179A
(ja)
|
2021-03-26 |
2024-03-12 |
モデルナティエックス インコーポレイテッド |
百日咳ワクチン
|
|
EP4314000A1
(en)
|
2021-03-31 |
2024-02-07 |
ModernaTX, Inc. |
Synthesis of trinucleotide and tetranucleotide caps for mrna production
|
|
EP4314046A4
(en)
|
2021-04-01 |
2025-03-19 |
ModernaTX, Inc. |
Mucosal expression of antibody structures and isotypes by mRNA
|
|
EP4314332A2
(en)
|
2021-04-01 |
2024-02-07 |
ModernaTX, Inc. |
Methods for identification and ratio determination of rna species in multivalent rna compositions
|
|
EP4322997A4
(en)
|
2021-04-13 |
2025-02-26 |
ModernaTX, Inc. |
EPSTEIN-BARR VIRUS mRNA VACCINES
|
|
AU2022258335A1
(en)
|
2021-04-13 |
2023-11-23 |
Modernatx, Inc. |
Respiratory virus combination vaccines
|
|
WO2022221336A1
(en)
|
2021-04-13 |
2022-10-20 |
Modernatx, Inc. |
Respiratory syncytial virus mrna vaccines
|
|
WO2022221440A1
(en)
|
2021-04-14 |
2022-10-20 |
Modernatx, Inc. |
Influenza-coronavirus combination vaccines
|
|
US20240238211A1
(en)
|
2021-04-23 |
2024-07-18 |
Modernatx, Inc. |
Isoquinoline-stabilized lipid nanoparticle formulations
|
|
EP4326227A1
(en)
|
2021-04-23 |
2024-02-28 |
ModernaTX, Inc. |
Stabilized formulations
|
|
EP4329731A1
(en)
|
2021-04-29 |
2024-03-06 |
ModernaTX, Inc. |
Lyophilization methods for preparing lipid formulated therapeutics
|
|
US20220363937A1
(en)
|
2021-05-14 |
2022-11-17 |
Armstrong World Industries, Inc. |
Stabilization of antimicrobial coatings
|
|
WO2022245888A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Seasonal flu rna vaccines and methods of use
|
|
EP4355761A1
(en)
|
2021-06-14 |
2024-04-24 |
ModernaTX, Inc. |
Mrna vaccines encoding flexible coronavirus spike proteins
|
|
EP4355891A4
(en)
|
2021-06-14 |
2025-09-24 |
Modernatx Inc |
VACCINES AGAINST CORONAVIRUS GLYCOSYLATION VARIANTS
|
|
WO2022266389A1
(en)
|
2021-06-17 |
2022-12-22 |
Modernatx, Inc. |
Alternative rna purification strategies
|
|
US20240358819A1
(en)
|
2021-07-09 |
2024-10-31 |
Modernatx, Inc. |
Pan-human coronavirus domain vaccines
|
|
US20240382581A1
(en)
|
2021-07-09 |
2024-11-21 |
Modernatx, Inc. |
Pan-human coronavirus vaccines
|
|
WO2023283642A2
(en)
|
2021-07-09 |
2023-01-12 |
Modernatx, Inc. |
Pan-human coronavirus concatemeric vaccines
|
|
US20250092440A1
(en)
|
2021-08-02 |
2025-03-20 |
Modernatx, Inc. |
Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
|
|
WO2023019181A1
(en)
|
2021-08-11 |
2023-02-16 |
Modernatx, Inc. |
Sars-cov-2 lipid nanoparticle vaccine formulations
|
|
WO2023018773A1
(en)
|
2021-08-11 |
2023-02-16 |
Modernatx, Inc. |
Lipid nanoparticle formulations and methods of synthesis thereof
|
|
US20240368580A1
(en)
|
2021-08-13 |
2024-11-07 |
Modernatx, Inc. |
Multicolumn chromatography mrna purification
|
|
WO2023056401A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating a disease or condition caused by or associated with human cytomegalovirus
|
|
WO2023069895A1
(en)
|
2021-10-18 |
2023-04-27 |
Modernatx, Inc. |
Markerless dna production
|
|
EP4419702A1
(en)
|
2021-10-18 |
2024-08-28 |
ModernaTX, Inc. |
Custom bacterial strain for recombinant protein production
|
|
US20250231165A1
(en)
|
2021-10-20 |
2025-07-17 |
Modernatx, Inc. |
Drug product surrogate solutions
|
|
WO2023076658A1
(en)
|
2021-11-01 |
2023-05-04 |
Modernatx, Inc. |
Mass spectrometry of mrna
|
|
US20240425902A1
(en)
|
2021-11-05 |
2024-12-26 |
Moderna TX, Inc. |
Methods of purifying dna for gene synthesis
|
|
WO2023092069A1
(en)
|
2021-11-18 |
2023-05-25 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines and methods of use
|
|
EP4444345A2
(en)
|
2021-12-08 |
2024-10-16 |
ModernaTX, Inc. |
Herpes simplex virus mrna vaccines
|
|
US20250067729A1
(en)
|
2021-12-15 |
2025-02-27 |
ModrnaTX, Inc. |
Determination of encapsulation efficiency of lipid nanoparticles
|
|
WO2023132885A1
(en)
|
2022-01-04 |
2023-07-13 |
Modernatx, Inc. |
Methods of purifying dna for gene synthesis
|
|
WO2023137149A1
(en)
|
2022-01-14 |
2023-07-20 |
Modernatx, Inc. |
In vitro transcription dna purification and recycling
|
|
JP2025506416A
(ja)
|
2022-02-03 |
2025-03-11 |
モデルナティエックス インコーポレイテッド |
ｍＲＮＡ精製のための連続的沈殿
|
|
WO2023154818A1
(en)
|
2022-02-09 |
2023-08-17 |
Modernatx, Inc. |
Mucosal administration methods and formulations
|
|
WO2023196914A1
(en)
|
2022-04-08 |
2023-10-12 |
Modernatx, Inc. |
Influenza nucleic acid compositions and uses thereof
|
|
EP4508242A1
(en)
|
2022-04-11 |
2025-02-19 |
ModernaTX, Inc. |
Detection of mrna purity in a mixture
|
|
WO2023201294A1
(en)
|
2022-04-14 |
2023-10-19 |
Modernatx, Inc. |
Rna polymerase variants
|
|
EP4508069A1
(en)
|
2022-04-15 |
2025-02-19 |
ModernaTX, Inc. |
Ribosomal engagement potency assay
|
|
WO2023212696A1
(en)
|
2022-04-29 |
2023-11-02 |
Modernatx, Inc. |
Lyophilized human cytomegalovirus vaccines
|
|
WO2023225524A1
(en)
|
2022-05-17 |
2023-11-23 |
Modernatx, Inc. |
Preparation of highly concentrated mrna
|
|
EP4544074A1
(en)
|
2022-06-24 |
2025-04-30 |
ModernaTX, Inc. |
Methods of producing rna
|
|
WO2024010993A1
(en)
|
2022-07-06 |
2024-01-11 |
Modernatx, Inc. |
Primer design for cell-free dna production
|
|
WO2024015890A1
(en)
|
2022-07-13 |
2024-01-18 |
Modernatx, Inc. |
Norovirus mrna vaccines
|
|
WO2024026005A1
(en)
|
2022-07-28 |
2024-02-01 |
Modernatx, Inc. |
Methods of rna purification
|
|
EP4565694A1
(en)
|
2022-08-01 |
2025-06-11 |
ModernaTX, Inc. |
Extraction-less reverse phase (rp) chromatography for mrna purity assessment
|
